Drug Development

Takeda rests its R&D footprint on U.S. hubs 

Back in late 2014, when Takeda announced that it had recruited Sanofi vet Andrew Plump as head of its R&D group, savvy observers were careful to note that Plump would be based in the Japanese company’s Boston hub. A few days ago, the Japanese pharma company unveiled its $725 million plan to reorganize R&D, pulling out of Cambridge, UK while concentrating much of the work in the Boston area. This chart from Takeda helps illustrate what’s going on in R&D, as the pharma company looks to expand on its links in the key hub while keeping San Diego in play for industry connections on the West Coast. Clearly, much of its future collaborative work will be done in the U.S. as CEO Christophe Weber methodically moves to change the culture at Takeda.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->